Skip to main content
. 2015 Jun 10;6(26):22666–22679. doi: 10.18632/oncotarget.4433

Figure 5. Nutlin-3 enhanced the apoptotic effect of CDDP in the p53 wild type cell line A549.

Figure 5

A. Relative mRNA expression levels of p53's main apoptotic targets PUMA and BAX. Cells were treated with either 2 μM CDDP; 5 μM, 10 μM or 25 μM Nutlin, or a sequential (CDDP -> Nutlin)/simultaneous combination therapy of both drugs for 24 hours. B. Corresponding protein levels of PUMA and BAX, β-actin was used as internal standard. C. Cells were labeled with Annexin V-FITC (AnnV) and Propidium Iodide (PI) and measured by flowcytometric analysis. Dot-plot: LL = AnnV-/PI-; LR = AnnV+/PI-; UR = AnnV+/PI+; UL = AnnV-/PI+. D. Percentage of Annexin V FITC positive cells. (*p < 0.05: significant difference compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM CDDP).